Amgenvs.Moderna
AMGN vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 7.2× larger than Moderna by market cap; year to date, Moderna leads (+131.5% vs +11.0%).
Side by side
| AMGN | MRNA | |
|---|---|---|
| Market cap | $196B | $27.2B |
| Price | $363.39 | $68.27 |
| Today | −0.1% | −10.8% |
| Return YTD | +11.0% | +131.5% |
| Return 1Y | +21.0% | +99.2% |
| P/E | 25.1 | — |
| P/S | 5.3 | 12.2 |
| P/B | 21.3 | 3.7 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AmgenAMGN
Veteran American biotech with a broad portfolio in oncology, immunology and bone diseases — and an obesity candidate (MariTide) in the pipeline.
Full AMGN profile →ModernaMRNA
American biotech company based on mRNA technology — known for the covid vaccine, with a pipeline in vaccines and oncology.
Full MRNA profile →More comparisons in Biotech & innovation
See where AMGN and MRNA sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →